Literature DB >> 9504836

Identification of plasma proteins facilitated by enrichment on particulate surfaces: analysis by two-dimensional electrophoresis and N-terminal microsequencing.

M Lück1, W Schröder, S Harnisch, K Thode, T Blunk, B R Paulke, M Kresse, R H Müller.   

Abstract

Plasma protein adsorption on intravenously injectable drug carriers is regarded as an important factor for the fate of the particles in the body after their administration. Therefore, the plasma protein adsorption patterns on a number of different carrier systems were analyzed in vitro employing two-dimensional electrophoresis (2-DE). The particulate systems presented in this study were polystyrene (PS) model particles, PS nanoparticles surface-modified by adsorption of a surfactant, a commercial fat emulsion, and magnetic iron oxide particles used as contrast agents in magnetic resonance imaging. Most of the spots in the plasma protein adsorption patterns could be identified by matching the resulting 2-DE gels with a reference map of human plasma proteins. Several other proteins that indicated preferentially adsorbed proteins on the surface of the particles investigated have either not been identified on the reference map, or their identity was found to be ambiguous. The relevant proteins are all present in plasma in low abundance. Since these proteins were strongly enriched on the surface of the particles, the resulting spots on the 2-DE gels were successfully identified by N-terminal microsequencing. With this approach, two chains of spots, designated PLS:6 and PLS:8, were determined on a plasma reference map: inter-alpha-trypsin inhibitor family heavy chain-related protein (also named PK-120) and a dimer of fibrinogen gamma, respectively. Plasma gelsolin is presented in a 2-DE adsorption pattern of PS model particles. One of the main proteins adsorbed by droplets of a commercial fat emulsion was identified as apoliprotein H. Moreover, the positions of apolipoproteins apoC-II and apoC-III were also verified on the 2-DE protein map of human plasma. Thus, protein adsorption experiments of the kind presented in this study are increasing our insight into human plasma proteins.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9504836     DOI: 10.1002/elps.1150181538

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  7 in total

Review 1.  Analytical strategies for detecting nanoparticle-protein interactions.

Authors:  Liwen Li; Qingxin Mu; Bin Zhang; Bing Yan
Journal:  Analyst       Date:  2010-05-26       Impact factor: 4.616

2.  Interaction of colloidal gold nanoparticles with human blood: effects on particle size and analysis of plasma protein binding profiles.

Authors:  Marina A Dobrovolskaia; Anil K Patri; Jiwen Zheng; Jeffrey D Clogston; Nader Ayub; Parag Aggarwal; Barry W Neun; Jennifer B Hall; Scott E McNeil
Journal:  Nanomedicine       Date:  2008-12-13       Impact factor: 5.307

3.  Polyelectrolyte-coated gold nanorods and their interactions with type I collagen.

Authors:  Christopher G Wilson; Patrick N Sisco; Francis A Gadala-Maria; Catherine J Murphy; Edie C Goldsmith
Journal:  Biomaterials       Date:  2009-07-30       Impact factor: 12.479

Review 4.  Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier.

Authors:  Julia V Georgieva; Dick Hoekstra; Inge S Zuhorn
Journal:  Pharmaceutics       Date:  2014-11-17       Impact factor: 6.321

Review 5.  Isolation methods for particle protein corona complexes from protein-rich matrices.

Authors:  Linda Böhmert; Linn Voß; Valerie Stock; Albert Braeuning; Alfonso Lampen; Holger Sieg
Journal:  Nanoscale Adv       Date:  2020-01-09

6.  Stealth properties to improve therapeutic efficacy of drug nanocarriers.

Authors:  Stefano Salmaso; Paolo Caliceti
Journal:  J Drug Deliv       Date:  2013-03-07

7.  Protein Adsorption Patterns and Analysis on IV Nanoemulsions-The Key Factor Determining the Organ Distribution.

Authors:  Cornelia M Keck; Mirko Jansch; Rainer H Müller
Journal:  Pharmaceutics       Date:  2012-12-21       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.